
Cristiano Caruso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1259685/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	lgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. Journal of Allergy and Clinical Immunology, 2010, 126, 994-999.	2.9	138
2	lgE-mediated hypersensitivity to cephalosporins: Cross-reactivity and tolerability of alternative cephalosporins. Journal of Allergy and Clinical Immunology, 2015, 136, 685-691.e3.	2.9	126
3	Cross-Reactivity and Tolerability of Cephalosporins in Patients with IgE-Mediated Hypersensitivity to Penicillins. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1662-1672.	3.8	111
4	Lipid transfer proteins: the most frequent sensitizer in <scp>I</scp> talian subjects with foodâ€dependent exerciseâ€induced anaphylaxis. Clinical and Experimental Allergy, 2012, 42, 1643-1653.	2.9	110
5	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respiratory Medicine,the, 2021, 9, 260-274.	10.7	102
6	Incidence of deep vein thrombosis among nonâ€ICU patients hospitalized for COVIDâ€19 despite pharmacological thromboprophylaxis. Journal of Thrombosis and Haemostasis, 2020, 18, 2358-2363.	3.8	96
7	Diagnosing nonimmediate reactions to cephalosporins. Journal of Allergy and Clinical Immunology, 2012, 129, 1166-1169.	2.9	82
8	Liver involvement is not associated with mortality: results from a large cohort of SARSâ€CoVâ€2â€positive patients. Alimentary Pharmacology and Therapeutics, 2020, 52, 1060-1068.	3.7	76
9	Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. Journal of Allergy and Clinical Immunology, 2015, 135, 972-976.	2.9	75
10	Natural evolution of skinâ€ŧest sensitivity in patients with IgEâ€mediated hypersensitivity to cephalosporins. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 806-809.	5.7	72
11	Cross-reactivity and tolerability of aztreonam and cephalosporins in subjects with a TÂcell–mediated hypersensitivity to penicillins. Journal of Allergy and Clinical Immunology, 2016, 138, 179-186.	2.9	64
12	Predicting <scp>Inâ€Hospital</scp> Mortality in <scp>COVID</scp> â€19 Older Patients with Specifically Developed Scores. Journal of the American Geriatrics Society, 2021, 69, 37-43.	2.6	62
13	One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101836.	2.6	57
14	Characteristics and treatment regimens across ERS SHARP severe asthma registries. European Respiratory Journal, 2020, 55, 1901163.	6.7	56
15	Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. Respiratory Medicine, 2020, 166, 105947.	2.9	55
16	A comparison of the performance of two penicillin reagent kits in the diagnosis of <i>β</i> â€lactam hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 53-58.	5.7	52
17	Drug allergy passport and other documentation for patients with drug hypersensitivity - An ENDA/EAACI Drug Allergy Interest Group Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1533-1539.	5.7	51
18	Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. Clinical and Experimental Allergy, 2011, 41, 96-103.	2.9	48

#	Article	IF	CITATIONS
19	Nasal cytology: Methodology with application to clinical practice and research. Clinical and Experimental Allergy, 2018, 48, 1092-1106.	2.9	47
20	Cross-reactivity among drugs: clinical problems. Toxicology, 2005, 209, 169-179.	4.2	46
21	Absence of cross-reactivity to carbapenems in patients with delayed hypersensitivity to penicillins. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1618-1621.	5.7	42
22	COVID-19 and intestinal inflammation: Role of fecal calprotectin. Digestive and Liver Disease, 2020, 52, 1231-1233.	0.9	40
23	The very limited usefulness of skin testing with penicilloylâ€polylysine and the minor determinant mixture in evaluating nonimmediate reactions to penicillins. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1104-1107.	5.7	38
24	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Realâ€life observation. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2539-2541.	5.7	36
25	Assessment of neurological manifestations in hospitalized patients with COVIDâ€19. European Journal of Neurology, 2020, 27, 2322-2328.	3.3	36
26	Aspirin challenge and desensitization: how, when and why. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 247-254.	2.3	32
27	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	3.5	30
28	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respiratory Medicine, 2020, 171, 106080.	2.9	28
29	Beta-lactam-induced immediate hypersensitivity reactions: AÂgenome-wide association study of a deeply phenotyped cohort. Journal of Allergy and Clinical Immunology, 2021, 147, 1830-1837.e15.	2.9	26
30	Non-immediate Cutaneous Reactions to Beta-Lactams: Approach to Diagnosis. Current Allergy and Asthma Reports, 2017, 17, 23.	5.3	25
31	Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organization Journal, 2018, 11, 33.	3.5	25
32	Celecoxib Tolerability in Patients with Hypersensitivity (Mainly Cutaneous Reactions) to Nonsteroidal Anti-Inflammatory Drugs. International Archives of Allergy and Immunology, 2005, 137, 145-150.	2.1	23
33	Etoricoxib Tolerability in Patients with Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs. International Archives of Allergy and Immunology, 2007, 143, 103-108.	2.1	23
34	Tolerability of Cefazolin and Ceftibuten in Patients with IgE-Mediated Aminopenicillin Allergy. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1989-1993.e2.	3.8	23
35	Real-life studies of biologics used in asthma patients: key differences and similarities to trials. Expert Review of Clinical Immunology, 2019, 15, 951-958.	3.0	20
36	Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis: A Multicenter Real-Life Experience. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 201-204.	1.3	20

#	Article	IF	CITATIONS
37	Efficacy of dupilumab in atopic comorbidities associated with moderateâ€ŧoâ€severe adult atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2653-2661.	5.7	20
38	β-Lactam Allergy and Cross-Reactivity: A Clinician's Guide to Selecting an Alternative Antibiotic. Journal of Asthma and Allergy, 2021, Volume 14, 31-46.	3.4	20
39	Angiotensinâ€converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVIDâ€19. Internal Medicine Journal, 2020, 50, 1483-1491.	0.8	19
40	A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. Journal of Dermatological Treatment, 2022, 33, 1146-1149.	2.2	19
41	Realâ€life impact of COVIDâ€19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2776-2784.	5.7	19
42	Omalizumab efficacy in a girl with atopic eczema. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 278-279.	5.7	18
43	Severe asthma: One disease and multiple definitions. World Allergy Organization Journal, 2021, 14, 100606.	3.5	18
44	Cross-Reactive Reactions to Nonsteroidal Anti-Inflammatory Drugs. Current Pharmaceutical Design, 2008, 14, 2826-2832.	1.9	16
45	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1460-1463.	5.7	16
46	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulmonary Pharmacology and Therapeutics, 2019, 54, 87-89.	2.6	15
47	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	3.5	14
48	ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. Respiratory Research, 2022, 23, 36.	3.6	14
49	Evaluating Immediate Reactions to Cephalosporins: Time Is of the Essence. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1648-1657.e1.	3.8	13
50	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	1.7	13
51	A Survey of Clinical Features of Allergic Rhinitis in Adults. Medical Science Monitor, 2014, 20, 2151-2156.	1.1	12
52	EAACI position paper on the clinical use of the bronchial allergen challenge: Unmet needs and research priorities. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1667-1684.	5.7	12
53	Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report. Allergy, Asthma and Clinical Immunology, 2020, 16, 27.	2.0	11
54	Allergenic significance of cephalosporin side chains. Journal of Allergy and Clinical Immunology, 2015, 136, 1426-1428.	2.9	9

#	Article	IF	CITATIONS
55	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. Alimentary Pharmacology and Therapeutics, 2020, 52, 902-903.	3.7	9
56	Effect of mepolizumab alone in chronic eosinophilic pneumonia relapse: A case report. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3640-3642.	3.8	9
57	Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. Frontiers in Allergy, 2022, 3, .	2.8	9
58	Delayed hypersensitivity to bosentan. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 499-501.	5.7	8
59	Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. Dermatology, 2022, 238, 717-724.	2.1	8
60	Detection of Serum-Specific IgE by Fluoro-Enzyme Immunoassay for Diagnosing Type I Hypersensitivity Reactions to Penicillins. International Journal of Molecular Sciences, 2022, 23, 6992.	4.1	8
61	Real-life survey on severe asthma patients during COVID-19 lockdown in Italy. Expert Review of Respiratory Medicine, 2021, 15, 1057-1060.	2.5	7
62	Prospective Italian realâ€world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. Clinical and Translational Allergy, 2021, 11, e12067.	3.2	7
63	Nasal Cytology: A Easy Diagnostic Tool in Precision Medicine for Inflammation in Epithelial Barrier Damage in the Nose. A Perspective Mini Review. Frontiers in Allergy, 2022, 3, .	2.8	7
64	Basophil activation and serum ILâ€5 levels as possible monitor biomarkers in severe eosinophilic asthma patients treated with antiâ€ILâ€5 drugs. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1569-1571.	5.7	6
65	Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study. BioMed Research International, 2020, 2020, 1-4.	1.9	5
66	Metabolomics, Microbiota, and In Vivo and In Vitro Biomarkers in Type 2 Severe Asthma: A Perspective Review. Metabolites, 2021, 11, 647.	2.9	5
67	Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. Expert Opinion on Pharmacotherapy, 2020, 21, 1283-1286.	1.8	4
68	Sameâ€patient allergy to ampicillin and human insulin. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1105-1107.	5.7	3
69	Reply. Journal of Allergy and Clinical Immunology, 2015, 136, 1428.	2.9	3
70	Efficacy of omalizumab treatment in a man with occupational asthma and eosinophilic granulomatosis with polyangioitis. Annals of Allergy, Asthma and Immunology, 2018, 120, 209-211.	1.0	3
71	Safety of an Accelerated Build-up Phase With Pollen Allergoids: A Retrospective Study. Journal of Investigational Allergology and Clinical Immunology, 2018, 28, 283-284.	1.3	2
72	Heterogeneous Condition of Asthmatic Children Patients: A Narrative Review. Children, 2022, 9, 332.	1.5	2

#	Article	IF	CITATIONS
73	Reply. Journal of Allergy and Clinical Immunology, 2016, 137, 331-332.	2.9	1
74	Diagnosing β-Lactam Hypersensitivity. Current Pharmaceutical Design, 2017, 22, 6803-6813.	1.9	1
75	Modulation of gut microbiota in patients with IBS and systemic nickel allergy after diet and probiotic supplementation: a pilot study. Journal of Biological Regulators and Homeostatic Agents, 2020, 34, 1929-1934.	0.7	1
76	Acquired cow's milk sensitization after liver transplant in an adult: "clinical implications―and future strategies. Allergy, Asthma and Clinical Immunology, 2019, 15, 11.	2.0	0
77	Patients' perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting. , 2017, , .		0
78	One year of mepolizumab in severe asthma in Italy: efficacy and safety. , 2019, , .		0
79	Switch Omalizumab – Mepolizumab: real life experience. , 2019, , .		0
80	Detection Of Serum Specific IgE By Fluoro-Enzyme Immunoassay For The Diagnosis Of Immediate Allergic Reactions To Penicillins. Journal of Allergy and Clinical Immunology, 2022, 149, AB80.	2.9	0